Alisma Shugan Decoction (ASD) Ameliorates Hepatotoxicity and Associated Liver Dysfunction by Inhibiting Oxidative Stress and p65/Nrf2/JunD Signaling Dysregulation In Vivo

Yunfeng Sun; Honghua Pan; Shenghui Shen; Zhongni Xia; Zhongmin Yu; ChengLe Li; Pingping Sun; Chuanwei Xin

doi:10.12659/MSM.921738

16 July 2020 : Animal Research

Alisma Shugan Decoction (ASD) Ameliorates Hepatotoxicity and Associated Liver Dysfunction by Inhibiting Oxidative Stress and p65/Nrf2/JunD Signaling Dysregulation In Vivo

Yunfeng Sun^12AEG, Honghua Pan^12CD, Shenghui Shen^23ABCF, Zhongni Xia^12BC, Zhongmin Yu^2ABCD, ChengLe Li^12F, Pingping Sun^12DEG, Chuanwei Xin^12DG*

DOI: 10.12659/MSM.921738

Med Sci Monit 2020; 26:e921738

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Figure 5 Pictorial abstract showing how Alisma Shugan Decoction (ASD) ameliorated hepatotoxicity and associated liver dysfunction. The present study provides new insights into the hepato-protective effects of ASD.

Back to the Article

Alisma Shugan Decoction (ASD) Ameliorates Hepatotoxicity and Associated Liver Dysfunction by Inhibiting Oxidative Stress and p65/Nrf2/JunD Signaling Dysregulation In Vivo

Your Privacy